Published in
BioMed Central, Hereditary Cancer in Clinical Practice, 1(14)
DOI: 10.1186/s13053-016-0048-3
Links
- ORCID
- BioMed Central | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [hccpjournal.biomedcentral.com] | PDF
Tools
Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality
Journal article published in 2016 by
D. Gareth Evans,
E. F. Harkness 
,
Anthony Howell,
M. Wilson,
E. Hurley,
M. M. Holmen,
K. U. Tharmaratnam,
A. I. Hagen,
Y. Lim,
A. J. Maxwell,
P. Moller
,
Anthony Howell,
M. Wilson,
E. Hurley,
M. M. Holmen,
K. U. Tharmaratnam,
A. I. Hagen,
Y. Lim,
A. J. Maxwell,
P. Moller
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data from BRCA2 mutation carriers undergoing intensive combined breast screening are scarce.